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Abstract
The resistance to inhibitors of tyrosine kinase necessitates novel approaches 
to the therapy of chronic myeloid leukemia (CML). The progression of CML to 
blast crisis is associated with down-regulation of C/EBP-alpha being involved in 
the differentiation block in leukemic blast cells. Moreover, lowered C/EBP-alpha 
expression correlates with resistance to imatinib in CML. We have demonstrated 
that vitamin E up-regulates expression of C/EBP-alpha and down-regulates expres-
sion of Snail transcription factor in K562 cells in vitro contributing to the putative 
recovery of myeloid differentiation potential. In parallel with increased CEBP alpha 
expression, Vitamin E treatment results in the decreasing expression of placental-
like alkaline phosphatase and increasing expression of tissue non-specific alkaline 
phosphatase. We suggest that vitamin E could be used as the plausible biological 
modulator to prevent the progression to blast crisis and to overcome drug resistance 
of leukemic cells in CML.
Keywords: chronic myeloid leukemia, vitamin E, C/EBP-alpha, Snail, K562 cells, 
drug resistance
1. Introduction
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell 
disorder associated with the activity of Bcr-Abl fusion oncogene that arises from the 
translocation of chromosomes 9 and 22 as t (9:22) (q34;q11) [1, 2]. The BCR/ABL 
fusion protein with elevated ABL tyrosine kinase activity is crucial for transforma-
tion of hematopoietic stem cells (HSCs) [3]. The constitutively active P210 BCR-
ABL tyrosine kinase is considered as a key player in the molecular pathogenesis of 
CML [3, 4]. The disease begins with an indolent chronic phase that can last for sev-
eral years. If untreated, it then progresses into accelerated phase and within a year 
into blast crisis phase. The survival of patients in blast crisis is less than one year. 
Because the preeminent rearrangement driving CML is Bcr-Abl, only BCR-ABL 
tyrosine kinase inhibitors such as imatinib (or nilotinib and dasatinib) are a known 
curative therapy of CML with extraordinarily successful 5-year survival rates 
greater than 90% [5–8]. Nevertheless, the secondary mutations finally contribute 
to the therapy resistance and blast crisis of the disease. The search for the novel 
compounds for the effective control of CML progression is now in the spotlight.
The free radical scavengers like alpha-tocopherol may be effective against 
cancer-associated oxidative stress. The mean serum vitamin E level significantly 
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decreased in CML patients that seems to be quite in agreement with free  radical 
involvement in CML progression [9]. In contrast to antioxidant function of 
vitamin E in CML, we suggest new modulation mechanisms of vitamin E that 
could be operative in prevention of CML progression. In particular, we analyzed 
the modulation function of vitamin E for molecular unblocking of myeloid dif-
ferentiation potential in CML cells via vitamin E-dependent induction of pivotal 
transcription factor CEBP alpha (CCAAT/enhancer-binding protein) as myeloid 
master regulator of myelopoiesis/granulopoiesis and consequently G-CSFR 
(granulocyte-colony stimulation factor receptor) [10]. Moreover, we have found 
that vitamin E could be involved in targeting epithelial-mesenchymal transition 
(EMT) mechanism in CML cells via SNAIL as EMT inducer [11, 12]. Therefore, 
we propose that vitamin E could be a therapeutic option when CML progresses 
in setting of imatinib therapy. Finally, since alkaline phosphatase is considered 
as a marker of stem cells [13], we studied the aberrant expression of placental-
like alkaline phosphatase (PLAP) and discovered the potential of vitamin E in 
remodeling of CML-associated aberrant expression of this enzyme [14]. Vitamin 
E-dependent induction of tissue non-specific alkaline phosphatase (TNAP) is 
paralleled by restored CEBP alpha expression as myeloid master regulator in CML 
cells [14].
Taken together, these findings suggest that vitamin E shows ability of remodel-
ing leukemic stem cell (LSC) phenotype in CML cells to hematopoietic stem cell 
(HSC) phenotype with myeloid differentiation potential development.
2.  Vitamin E activates expression of C/EBP alpha transcription factor 
and G-CSF receptor in CML blast crisis leukemic K562 cells
C/EBPα is mainly involved in cell fate decisions for myeloid differentiation 
[15]. The progression of CML to blast crisis is correlated with down-modulation 
of C/EBP-alpha contributing to the differentiation block, enhanced proliferation, 
and development of acute myelogenous leukemia [16, 17]. The level of C/EBPα 
expression is significantly declined in CML patients [18]. Currently, the deregula-
tion of C/EBP alpha is considered as a paradigm of leukemogenesis [19]. Therefore, 
C/EBPα is a critical regulator of myeloid development guiding granulocyte and 
monocyte differentiation.
We have studied the modulating potential of vitamin E as the possible inducer 
of C/EBP-alpha expression in BCR-ABL-positive CML K562 cells. K562 cell line 
originated from a CML patient in blast crisis progression is recognized as a model 
for leukemia research. We studied the effects of vitamin E in K562 cells in com-
parison with valproic acid with known differentiation properties towards myeloid 
cells [20–22].
Valproic acid in a concentration of 4 mM for 48 h reduced the growth rate and 
cell viability and induced apoptosis in a fraction of K562 cells (up to 30%). As to 
vitamin E, in the series of our preliminary experiments, no evidence of toxicity has 
been demonstrated when K562 cells were cultured with vitamin E in a concentration 
of 100 μM for 48 h. These concentrations were further used in the experiments for 
assaying the expression of C/EBP-alpha and G-CSFR mRNA. Figure 1 A demon-
strates that valproic acid did not change significantly the level of mRNA C/EBP 
expression in K562 cells. On the contrary, vitamin E proved to be an effective inducer 
of mRNA C/EBP with about 10-fold increase in expression as compared with non-
treated K562 cells. When mRNA G-CSFR expression in K562 cells was assessed, both 
valproic acid and vitamin E induced mRNA of this receptor, with effect of vitamin E 
surpassed that of VA (Figure 1A and Table 1).
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Thease findings are quite confirmed by Tavor et al. [23] have first shown that the 
restoration of C/EBP-alpha expression in BCR-ABL-positive KCL22 blast cell line 
provided by transfection with C/EBPα plasmid vector caused a block in the G2/M 
phase of the cell cycle with gradual increase in apoptosis suggesting that C/EBP-alpha 
may be considered as a putative target in differentiation therapies in acute myeloid 
Figure 1. 
mRNA expression in CML cells modified by vitamin E. (A) The relative levels of mRNA C/EBP-alpha and 
G-CSFR expression in K562 cells exposed to valproic acid (2 mM) or vitamin E (100 μM) for 48 h. (B) The 
aberrant AP mRNA detected by qRT-PCR in leukemic cells of the patient with CML blast crisis: 1 – control 
without primers; 2 – primers to PAP; 3 – primers to TNAP; 4 – primers to IAP. (C) Ectopic gene expression of 
embryonic PLAP mRNA in peripheral blood cells of the patient with CML, acute myeloid leukemia (AML), 
and polycytemia vera (PV): 1 – GAPDH, reference gene; 2 – aberrant PLAP. (D) The relative levels of mRNA 
expression of PLAP, TNAP, and CCAAT-enhancer binding protein alpha (C/EBPα) in K562 cells exposed 
to vitamin E (100 μM) for 48 h by real time RT-PCR 2¯(ΔCt) method. (E) Relative mRNA expression level of 
transcription factor Snail and transcription factor CEBPα in CML blast crisis K562 cells exposed to vitamin E 
(100 μM) and metformin (4 mM) for 48 h. The relative levels of mRNA expression were analyzed by  
qRT-PCR and calculated by 2¯(ΔCt) method.
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leukemia. C/EBPα directly activates G-CSFR transcription in lineage committing 
activation of common myeloid progenitor [24–26]. Therefore, C/EBPα loss is causally 
connected with early block in myeloid maturation suggesting that C/EBPα is a master 
regulator of hematopoietic differentiation. The transcription factor C/EBPα is known 
as a critical regulator of myeloid development, directing granulocyte, and monocyte 
differentiation [27].
Our findings gave evidence of C/EBP alpha-dependent activation to granu-
locytic differentiation via targeted increase in G-CSFR expression in vitamin E 
treated K562 cells. It should be further elucidated whether such effects of vitamin E 
on myeloid transcription factor C/EBP-alpha are direct or mediated indirectly due 
to the antioxidant properties of vitamin E. Nevertheless, our data suggest vitamin 
E-associated hematopoietic differentiation-like potential associated with C/EBPα 
and G-CSFR up-regulation. Our findings might be very important for future studies 
of imatinib resistance in CML clinical setting taking into account the recent report 
by S. Kagita et al. demonstrating correlation of C/EBPα expression with response 
and resistance to imatinib in CML [28].
3.  Aberrant expression of placental-like alkaline phosphatase in chronic 
myeloid leukemia cells in vitro and its modulation by vitamin E
LSCs in CML do not depend on BCR-ABL signaling for their survival [29, 30], 
and their persistence remains a major obstacle to curing CML [31, 32]. The search 
for new biological markers of LSC phenotype is still relevant today. Placental-like 
alkaline phosphatase (PLAP) is expressed by many tumors. Its aberrant expression 
has been considered to be potentially useful as tumor marker [33]. However, the 
biological background of the role of this aberrant alkaline phosphatase (AP) in 
cancer is still unclear. The AP activity in blood serum known as nonspecific marker 
of bone metastasis [33] is also of potential significance for the identification of 
stem cell phenotype [13, 34]. Moreover, AP activity is a widely accepted marker 
of stem cells associated with embryonic stem cell pluripotency [35]. The expres-
sion of various forms of AP in CML cells has not yet been studied. Therefore, we 
aimed to analyze the expression patterns of various AP forms in cells originated 
from CML patients in blast crisis and to modify their expression by vitamin E 
(100 μM) in K562 cells. We used the primers to three known tissue AP, namely 
placental AP (PAP), non-specific AP (TNAP) (expressed in bone, kidney, liver) 
and intestinal AP (IAP) [36] to analyze the mRNA expression of these APs in 
CML cells by qRT-PCR. We have observed the aberrant expression of mRNA IAP 
in cells of CML patient in blast crisis (Figure 1B) that upon sequencing (data not 
shown) demonstrated the significant alignment with known cancer-associated 
PLAP sequence, while no gene homology with tissue PAP was detected. This fact 
N (n = 3) C/EBP alpha G-CSFR
Fold increase Standard Deviation, σ Fold increase Standard Deviation, σ




Fold increase C/EBP alpha and G-CSFR mRNA expression (analyzed in triplicates) in gene expression in 
K562 cells line culture under 48-h vitamin E exposure (100 μM) calculated by 2−(∆∆Ct) method. Note: σ = √ 1/n 
∑(xi – x¯)2.
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gave reason to consider revealed PLAP as embryonic-like placental AP (ELAP), 
to be more precise, the aberrant PLAP in blast cells of CML patients (Figure 1C). 
Indeed, such PLAP is expressed in early embryo pre-implantation period as was 
detected in studying mouse embryonic cell development, while tissue TNAP begins 
to express in post-implantation period [35]. We have not detected TNAP in cells 
of CML patients. Only the embryonic-like PLAP was detected, which expression 
also increased in acute myeloid leukemia (Figure 1C). Recently, TNAP recognized 
ultimately as mesenchymal stromal cell antigen-1 (MSCA-1) [13] was described 
as a biomarker associated with normal hematopoiesis as well as with terminal 
myeloid differentiation [37]. The decreased TNAP synthesis is a classical feature of 
CML used as one of diagnostic cytochemical markers in differential diagnosis [2]. 
We have observed vitamin E targeted decrease in aberrant embryonic-like PLAP 
expression at mRNA level with increased TNAP mRNA expression. Moreover, along 
with down-regulation of aberrant PLAP the up-regulation of C/EBP alpha mRNA 
expression was restored by vitamin E in exposed K562 cells as we founded (Figure 
1D and Table 2).
Taken together, we have concluded that the loss of TNAP and CEBP alpha in 
CML may contribute to pathogenesis of this disease whereas aberrant embryonic-
like PLAP may be considered as a new CML biomarker of LSC pluripotent phe-
notype in CML progression. Therefore, aberrant embryonic-like PLAP may be 
considered as a putative target in differentiation therapies in myeloid neoplasms. 
Our findings suggest the biomodulation role of vitamin E as the available inducer 
of differentiation potential of CML leukemic cells. The ectopic PLAP expression in 
leukemic cells of different myeloid neoplasms suggests its importance in biology of 
these malignancies.
Conclusivelly, to analyze whether ectopic PLAP expression in CMLcells in vitro 
may be modulated, we studied PLAP and TNAP expression in CML blast crisis 
K562 leukemic cells incubated with vitamin E for 48 h. In fact, vitamin E treatment 
affects expression of PLAP and TNAP in opposite ways. Namely, PLAP expression 
decreased significantly while TNAP expression increased. The increase in TNAP 
expression was paralleled with increased CEBP alpha expression (Figure 1D and 
Table 2). Figure 1, D demonstrates that vitamin E targeted aberrant PLAP expres-
sion is closely related to the restoration of CEBP alpha and TNAP expression. These 
key regulators tightly contribute to potential reactivation of myeloid differential as 
we studied in K562 leukemic cells. Therefore, we point out that vitamin E could be 
able to affect leukemic blast stem cell phenotype remodeling.
To sum up, we have demonstrated increased aberrant PLAP expression in 
leukemic cells of myeloid origin (CML) in the setting of the decreased TNAP 

















1 4.088 ± 0.322 1.42 2.972 ± 1.594 1.35 6.023 ± 2.809 1.98
2 6.292 ± 1.883 4.377 ± 0.117 1.690 ± 1.524 
3 2.848 ± 1.561 6.207 ± 1.713 1.931 ± 1.283 
Table 2. 
The relative fold decreasing PLAP corresponding to fold increasing CEBP α and TNAP mRNA expression 
(analyzed in triplicates) in gene expression in K562 cells line culture under 48-h vitamin E exposure (100 μM) 
calculated by 2−(∆∆Ct) method. Note: σ = √ 1/n ∑(xi – x¯)2.
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one of the putative markers of myeloid cell undifferentiated state. On the other 
hand, potential of PLAP as one of the possible target for controlling LSC pheno-
type should be further explored. More attention is needed to explore the potential 
of the bioactive molecules such as vitamin E that may induce granulopoiesis 
reprogramming.
4.  Vitamin E suppresses EMT-SNAIL transcription factor and restores 
CEBP alpha transcription factor as master regulator of myelopoiesis 
in K562 cells
The persistence of LSC remains a major obstacle to cure CML [38, 39]. Epithelial 
mesenchymal transition (EMT) mechanism is known to contribute to tumor stem cell 
progression [40, 41]. Although EMT has been studied in relation to epithelium-derived 
tumors, there is increasing evidence implicating the involvement of EMT activators 
in hematopoietic malignancies [42, 43]. The expression of some EMT modulators has 
been demonstrated in Ph + leukemia cells [44]. EMT inducer Snail if of most impor-
tant role in maintaining stemness properties in tumor progression [45, 46]. It was 
shown that Snail also drives LSC phenotype in leukemia progression [44, 47]. Earlier, 
we revealed that alpha-tocopherol might be an effective inducer of mRNA CEBP alpha 
in K562 cells in vitro [10]. The loss of C/EBPα contributes to leukemogenesis [16, 19] 
and CEBP alpha expression prevents from appearance of EMT phenotype [48].
We have determined the relationship between EMT-Snail suppression and 
restored CEBP alpha myeloid differentiation potential in CML blast crisis K562 cells 
exposed to vitamin E. Metformin as known substance mediating EMT reversal [49] 
was used to compare EMT suppression effect of vitamin E in K562 cells.
We have found highly detectable Snail1 mRNA expression and down-regulated 
CEBP alpha in K562 cells (Figure 1E). Vitamin E suppressed EMT-Snail mRNA 
expression and up-regulated myeloid master regulator CEBP alpha mRNA expression 
(Figure 1E and Tables 3, 4). Such reactivation of CEBP alpha is enhanced by metfor-
min pointing to the possible synergistic effect with alpha-tocopherol. We observed that 
vitamin E is a modulator of gene expression that affects Snail1 and CEBP alpha mRNA 
expression in K562 cells in opposite directions. One could suggest the causal relation-
ship between EMT-Snail1 suppression and restoration of CEBP alpha expression that 
seems to contribute to recover myeloid differentiation potential of CML blast cells. As 
seen in Figure 1E, myelopoietic master regulator C/EBPα is also restored upon metfor-
min treatment, although the effect of vitamin E is more pronounced (Table 4).
Taken together, schematic model of the Vitamin E modulation effects in CML 
blast crisis progression with Snail-EMT phenotype is presented (Figure 2).









Fold increase EMT-inducer transcription factor SNAIL mRNA expression (analyzed in triplicates) in gene 
expression in K562 cells line culture under 48-h vitamin E exposure (100 μM) calculated by 2−(∆∆Ct) method. 
Note: σ = √ 1/n ∑(xi – x¯)2.
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5. Discussion
CML is characterized by an accelerated and unregulated proliferation of 
predominantly myeloid cells in the bone marrow with their accumulation in the 
blood. CML develops as a result of malignant transformation and clonal prolifera-
tion of pluripotent hematopoietic stem cells (HSCs), leading to overproduction 
of immature myeloid progenitor cells that results in blast cell crisis. The CML 
blast crisis resembles acute leukemia. Because the preeminent mutation driving 
CML is Bcr-ABL thyrosine kinase oncogene, the use of Bcr-Abl kinase inhibi-
tors (TKIs), such as imatinib, dasatinib, and nilotinib, significantly improves 
treatment outcomes and extends the life expectancy of CML patients. However, 
imatinib resistance drives blast crisis progression. The persistence of LSCs remains 
a major obstacle to cure CML. The clinical CML blast crisis progression with LSC 
phenotype is practically incurable. Therefore, the blocking of terminal myeloid 
differentiation and LSC phenotype development defines a putatively new strategy 
for CML prevention.
The potential of vitamin E in regulation of these interdependent mechanisms 
in CML progression was hinted by several observations that were reported earlier. 
Sangodkar et al. [50] showed that vitamin E activates PP2A phosphatase resulting 
in Bcr-Abl thyrosine kinase inhibition and re-activation of myeloid differentiation 
















1 5.156 ± 0.328 0.232 5.564 ± 0.075 0.371 2.841 ± 0.007 0.272
2 4.634 ± 0.194 5.00 ± 0.489 3.164 ± 0.330
3 4.696 ± 0.132 5.902 ± 0.413 2.498 ± 0.336
Table 4. 
The fold increase of relative levels of the transcription factor CEBP alpha mRNA expression compared with 
metformin (4 mM) under decreasing of relative levels of the transcription factor Snail mRNA expression 
by vitamin E (analyzed in triplicates) in K562 cells line culture under 48-h vitamin E exposure (100 μM) 
calculated by 2−(∆∆Ct) method. Note: σ = √ 1/n ∑(xi – x¯)2.
Figure 2. 
Schematic model of the vitamin E modulation in CML progression with EMT phenotype.
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pathway. In BCR/ABL transformed cells and CML blast crisis hematopoietic 
progenitors, the PP2A activity is strongly inhibited, while the pharmacological 
activation of PP2A suppresses BCL/ABL activity and induces BCR/ABL degradation 
[51]. The pharmacological modulation of PP2A activity is becoming an attractive 
strategy for cancer treatment. The substances of several different classes are known 
as PP2A activating compounds, vitamin E (α-tocopherol) and its analogues having 
been reported among such compounds [50, 52].
Nevertheless, the effects of vitamin E on differentiation pathways in cells of 
blast crisis CML, in particular those involving restoration of the expression of 
CCAAT-enhancer binding protein alpha (C/EBPα) and granulocyte colony-stimu-
lating factor receptor (G-CSFR) have not been yet studied. The expression of these 
proteins decreases drastically in chronic phase and blast crisis of CML [53, 54]. 
In this regard, we evaluated the effect of vitamin E on RNA expression of crucial 
factors of myeloid differentiation, C/EBRα and G-CSFR, in BCR-ABL-positive CML 
blast crisis K562 cells. Our data demonstrate that vitamin E restores the expression 
of C/EBPα and concequently G-CSFR. Our results are consistent with Tavor et al. 
[23] who demonstrated that the restoration of C/EBPα expression in BCR-ABL-
positive KCL22 blast cell line triggered a proliferative arrest, a block in the G2/M 
phase of the cell cycle and a gradual increase in apoptosis suggesting the activation 
of differentiation. Therefore, C/EBPα stimulated by vitamin E may be considered as 
a putative target in differentiation therapies in myeloid leukemias.
The second effect of vitamin E potentially useful for CML treatment was 
reported by Nieborowska-Skorska et al. [55] who demonstrated that vitamin E 
prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in mice 
CML xenografts. The authors stressed anti-oxidant function of vitamin E in this 
processes. We use vitamin E as modulating factor in CML that involves vitamin 
E-dependent EMT mechanism of repression taking into account the pivotal role of 
EMT in the development of LSC phenotype. In this connection, we observed Snail1 
overexpression suggesting some features of EMT phenotype in K562 cells seemingly 
contributing to CML pathogenesis. Furthermore, we have determined down-
regulation of CEBP alpha transcription factor representing the master regulator of 
myelopoiesis in CML cells coinciding with Snail1 overexpression. Our findings are 
quite consistent with the recent report by Lourenço et al. [43] who suggest that C/
EBP α is crucial determinant of epithelial maintenance by preventing EMT. Indeed, 
we have found that CEBP alpha is repressed by overexpression of EMT-inducer 
Snail in CML blast crisis K562 cells. Consequently, the reactivation of CEBP alpha 
by vitamin E is paralleled by suppression of Snail.
Therefore, our findings make deeper understanding of the role of vitamin E in 
suppression of CML LSC phenotype. In addition, we have revealed a new marker – 
aberrant placental-like alkaline phosphatase (PLAP) that expressed ectopically in 
CML progression. Moreover, its suppression by vitamin E consequently re-activates 
CEBP alpha and TNAP as myeloid differentiation factors. Taken together, our find-
ings presented in this Chapter stress the role of vitamin E in modifying expression 
profile of CML cells towards restoration of myeloid differentiation potential.
6. Conclusion
Vitamin E is a complex group of lipid-soluble antioxidants comprising four 
tocopherols and four tocotrienols. It prevents production of reactive oxygen species 
(ROS) that are elevated in majority of tumor cells leading to lipid peroxydation, 
changing signaling pathways that control cell proliferation and apoptosis, expres-
sion of several transcription factors, epigenetic modulators, resistance to treatment, 
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etc. We have suggested the causal relationship between EMT-Snail1 suppression and 
restoration of CEBP-alpha myeloid master regulator expression that seems to con-
tribute to recover myeloid differentiation potential of CML blast cells by vitamin E. 
We first observed that vitamin E is an effective modulator of down-regulation of 
transcription factor Snail EMT-inducer and up-regulation of pivotal myelopoietic 
transcription factor CEBP alpha resulting in restoration of TNAP expression. Taken 
into account the data of literature and our findings, we can postulate that vitamin 
E might be used as a potential pharmacopoeian biological modulator capable of 
preventing the onset of blast crisis development, ameliorating disease progression 
and possibly overcoming drug resistance of leukemic cells in CML patients.
Additional information
All authors of chapter are Laureates of the National  Award of the Cabinet 
of Ministers of Ukraine for the development and implementation of innovative 
technologies in the field of Biomedicine (N289.p from May 10, 2018).
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
10
Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects
[1] Calabretta B, Perrotti D. The 
biology of CML blast crisis. Blood. 
2004; 103: 4010-4022. DOI: 10.1182/
blood-2003-12-4111.
[2] Gluzman DF, Sklyarenko LM,  
Nadgornaya VA. Tumours of 
hematopoietic and lymphoid 
tissues (Cytomorphology, Immuno-
cytochemistry, Diagnostic Algorithms). 
DIA, Kiev, 2008 (in Russian).
[3] Satter M, Griffin JD. Molecular 
mechanisms of transformation by 
the BCR-ABL oncogene. Seminars 
in Hematology. 2003; 40: 4-10. DOI: 
10.1053/shem.2003.50034.
[4] Morotti A, Panuzzo C, Fava C, 
Saglio G. Kinase-inhibitor-insensitive 
cancer stem cells in chronic myeloid 
leukemia. Expert Opinion in Biological 
Therapy. 2014; 14: 287-299. DOI: 
10.1517/14712598.2014.867323.
[5] Soverini S, Mancini M, Bavaro L, 
et al. Chronic myeloid leukemia: the 
paradigm of targeting oncogenic 
tyrosine kinase signaling and 
counteracting resistance for successful 
cancer therapy. Molecular Cancer. 
2018; 17 (1): 49. DOI: 10.1186/
s12943-018-0780-6.
[6] Mauro MJ. Goals for chronic myeloid 
leukemia TK inhibitor treatment: 
how little disease is too much? 
Hematology ASH Education Program. 
2014; (1): 234-239. DOI: 10.1182/
asheducation-2014.1.234.
[7] Stango F, Stella S, Spitaleri A, et al. 
Imatinib mesylate in chronic myeloid 
leukemia: frontline treatment and 
long-term outcomes. Expert Reviews 
Anticancer Therapy. 2016;16(3):273-278. 
DOI: 10.1586/14737140.2016.
[8] Claudiani S., Apperley J.F. The 
argument for using imatinib in CML. 
Hematology ASH Education Program. 
2018(1): 161-167. DOI: 10.1182/
asheducation-2018.1.161.
[9] Singh V, Kharb S, Ghalaut PS, 
Gupta S. Serum vitamin E in chronic 
myeloid leukaemia. Journal of 
Association of Physicians India. 2000; 
48(2):201-203. PMID: 11229147.
[10] Shvachko LP, Zavelevich MP, 
Gluzman DF, Telegeev GD, et al. 
Vitamin Е activates expression of  
С/EBP alpha transcription factor and 
G-CSF receptor in leukemic K562 cells. 
Experimental Oncology. 2018; 40(4): 
328-231. PMID: 30593760.
[11] Bhamidipati PK, Kantarjian H, 
Cortes J, et al. Management of imatinib-
resistant patients with chronic myeloid 
leukemia. Therapy Advances in 
Hematology. 2013; 4(2): 103-117. DOI: 
10.1177/2040620712468289.
[12] Shvachko LP, Zavelevich MP, 
Gluzman DF, Telegeev GD. Vitamin E 
suppresses Snail transcription factor 
and restored CEBP alpha transcription 
factor as master regulator of 
myelopoiesis in K562 cells. – The Virtual 
Congress on Controversies in Leukemias 
(EUROLEUK2020), 29-30 October 
2020, Online. List E-Poster N5;
[13] Sobiesiak M, Sivasubramaniyan K, 
Hermann C, et al. The mesenchymal 
stem cell antigen MSCA-1 is identical to 
tissue non-specific alkaline phosphatase. 
Stem Cells and Development. 
2010; 19(5): 669-677. DOI: 10.1089/
scd.2009.0290.
[14] Shvachko LP, Zavelevich MP, 
Gluzman DF, Telegeev GD. Aberrant 
expression of placental-like alkaline 
phosphatase in chronic myeloid 
leukemia cells in vitro and its 
modulation by vitamin E. Experimental 
Oncology. 2020; 42 (1): 1-4 . DOI: 
References
11




[15] Avellino R, Delvel R. Expression 
and regulation of C/EBPα in normal 
myelopoiesis and in malignant 
transformation. Blood 2017; 129: 
2083-2091. https://doi.org/10.1182/
blood-2016-09-687822.
[16] Porse BT, Bryder D, Theilgaard- 
Monch K, et al. Loss of C/EBP alpha 
cell cycle control increases myeloid 
progenitor proliferation and transforms 
the neutrophil granulocyte lineage. 
Journal of Experimental Medicine. 
2005; 202: 85-96. DOI: 10.1084/
jem.20050067.
[17] Perrotti D, Cesi V, Trotta R, et al. 
BCR/ABL suppresses C/EBR alpha 
expression through inhibitory action 
of RNPE2. Nature Genetics. 2002; 30: 
48-58. DOI: 10.1038/ng791.
[18] Dong F, Zhang G, Zhang X, et al. 
Aberrantly expressed transcription 
factors C/EBP and SOX4 have positive 
effects in the development of chronic 
myeloid leukemia. Molecular Medicine 
Reports. 2017; 16: 7131-7137. https://doi.
org/10.3892/mmr.2017.7486.
[19] Pullikan JA, Tenen DG, Behre G. C/
EBPα deregulation as a paradigm for 
leukemogenesis. Leukemia. 2017; 31: 
2279-2285. DOI: 10.1038/leu.2017.229.
[20] Sasaki K, Yamagata T, 
Mitani K. Histone deacetylase inhibitors 
trichostatin A and valproic 
acid circumvent apoptosis in 
human leukemic cells expressing 
the RUNX1 chimera. Cancer 
Science. 2008; 99: 414-422. 
DOI:10.1111/j.1349-7006.2007.00699.x.
[21] Liu N, Wang C, Wang L, et al. 
Valproic acid enhances the antileukemic 
effect of cytarabine by triggering 
cell apoptosis. International Journal 
of Molecular Medicine. 2016; 37, 
1686-1696. https://doi.org/10.3892/
ijmm.2016.2552
[22] Zapotocky M, Mejstrikova E, 
Smetana K, et al. Valproic acid triggers 
differentiation and apoptosis in AML1/
ETO-positive leukemic cells specifically. 
Cancer Letters. 2012; 319: 144-153. DOI: 
10.1016/j.canlet.2011.12.041.
[23] Tavor S, Park DJ, Gery S, et al. 
Restoration of C/EBPalpha expression in 
a BCR-ABL+ cell line induces terminal 
granulocytic differentiation. Journal of 
Biological Chemistry. 2003; 278: 52651-
52659. DOI: 10.1074/jbc.M307077200.
[24] Wang Q.F., Friedman A.D. CCAAT/
enhancer-binding proteins are required 
for granulopoiesis independent of their 
induction of the granulocyte colony-
stimulating factor receptor. Blood. 2002; 
99: 2776-2785. DOI: 10.1182/blood.
v99.8.2776.
[25] Zhang P, Wang ND, Hetherington CJ, 
Darlington GJ, Tenen DG. Absence of 
granulocyte colony-stimulating factor 
signaling and neutrophil development 
in CCAAT enhancer binding protein 
alpha-deficient mice. Proceedings of 
the National Academy of Sciences USA. 
1997; 94: 569-574. DOI: 10.1073/
pnas.94.2.569.
[26] Nakajima H, Ihle JN. Granulocyte 
colony-stimulating factor regulates 
myeloid differentiation through 
CCAAT/enhancer-binding protein 
epsilon. Blood. 2001; 98: 897-905. DOI: 
10.1182/blood.v98.4.897.
[27] Paz-Priel I, Friedman AD. C/EBPα 
dysregulation in AML and ALL. Critical 
Reviews in Oncogenesis. 2011; 16: 
93-102. DOI: 10.1615/critrevoncog.v16.
i1-2.90.
[28] Kagita S, Uppalapati S, Gungeti S, 
Digumarti R. Correlation of C/EBPα 
expression with response and resistance 
to imatinib in chronic myeloid leukemia. 
Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects
12
Japanese Journal of Clinical Oncology. 
2015; 45: 749-754. DOI:org/10.1093/
jjco/hyv064
[29] Loscocco F, Visani G,  
Galimberti S, et al. BCR-ABL 
Independent Mechanisms of Resistance 
in Chronic Myeloid Leukemia. Frontiers 
in Oncology. 2019; 9: 939. DOI:10.3389/
fonc.2019.00939
[30] Corbin AS, Agarwal A, Loriaux M, 
et al. Human chronic myeloid leukemia 
stem cells are insensitive to imatinib 
despite inhibition of BCR-ABL activity. 
Journal of Clinical Investigations. 
2011; 121: 396-409. DOI: 10.1172/
JCI35721.
[31] Chomel JC, Bonnet ML, Sorel N, 
et al. Leukemic stem cell persistence 
in chronic myeloid leukemia 
patients with sustained undetectable 
molecular residual disease. Blood 
2011; 118: 3657-3660. DOI: 10.1182/
blood-2011-02-335497.
[32] Chu S, McDonald T, Lin A, et al. 
Persistence of leukemia stem cells 
in chronic myelogenous leukemia 
patients in prolonged remission 
with imatinib treatment. Blood. 
2011; 118: 5565-5572. DOI: 10.1182/
blood-2010-12-327437.
[33] Metwalli AR, Rosner IL, Cullen J, 
et al. Elevated alkaline phosphatase 
velocity strongly predicts overall 
survival and the risk of bone 
metastases in castrate resistant 
prostate cancer. Urological Oncology. 
2014; 32(6): 761-768.DOI: 10.1016/j.
urolonc.2014.03.024.
[34] Stefkova K, Prochazkova J, 
Pachernik J. Alkaline phosphatase in 
stem cells. Stem Cells International. 
2015; 2015: 628368. DOI: 
10.1155/2015/628368.
[35] Hahnel AC, Rappolee DA, Millan JL, 
et al. Two alkaline phosphatase genes 
are expressed during early development 
in the mouse embryo. Development. 
1990; 110 (2): 555-564. PMID: 2133555
[36] Sharma U, Pal D, Prasad R. Alkaline 
phosphatase: An overview. Indian 
Journal of Clinical Biochemistry. 
2014; 29(3): 269-278. DOI: 10.1007/
s12291-013-0408-y.
[37] Kim YH, Yoon DS, Kim HO, 
Lee JW. Characterization of different 
subpopulations from bone marrow-
derived mesenchymal stromal cells by 
alkaline phosphatase expression. Stem 
Cells and Development 2012; 21(16): 
2958-2968. DOI: 10.1089/scd.2011.0349.
[38] Jamieson CH. Chronic myeloid 
leukemia stem cells. Hematology ASH 
Education Program. 2008; 436-442. 
DOI: 10.1182/asheducation-2008.1.436.
[39] Crews L.A., Jamiesson C.H.M. 
Chronic Myeloi-d Leukemia Stem 
Cell Biology. Current Hematological 
Malignancies Reports. 2012; 7(2):125-
132. DOI: 10.1007/s11899012-0121-6
[40] Liu X, Fan D. The epithelial-
mesenchymal transition and cancer 
stem cells: functional and mechanistic 
links. Current Pharmacology Design. 
2015; 21(10):1279-1291. DOI: 10.2174/13
81612821666141211115611.
[41] Jolly MK, Huang B, Lu M. et al. 
Towards elucidating the connection 
between epithelial mesenchymal 
transitions and stemness. Journal 
of Royal Society Interface. 2014; 
11: 20140962. DOI: 10.1098/
rsif.2014.0962.
[42] Chen S., Liao T., Yang M. Emerging 
roles of epithelial-mesenchymal 
transition in hematological 
malignancies. Journal of Biomedical 
Sciences. 2018; 25: 37. DOI: 10.1186/
s12929-018-0440-6.
[43] PuissantA., Dufies M., Fenouille N. 
et al. Imatinib triggers mesenchymal-
like conversion of CML cells associated 
13
Vitamin E in Chronic Myeloid Leukemia (CML) Prevention
DOI: http://dx.doi.org/10.5772/intechopen.96452
with increased aggressiveness. Journal 
of Molecular Cell Biology. 2012; 4(4): 
207-220. DOI: 10.1093/jmcb/mjs010
[44] Kidan NH, Ruimi N, Roitman Sh. 
Ectopic expression of Snail and Twist 
in Ph+ leukemia cells upregulates 
CD44 expression and alters their 
differentiation potential. Journal of 
Cancer. 2017; 8(8): 3952-3968. DOI: 
10.7150/jca.19633.
[45] Wang Y, Shi J, Chai K. et al. 
The role of Snail in EMT and 
tumorigenesis. Current Cancer Drug 
Targets. 2013; 13(9): 963-972. DOI: 
10.2174/15680096113136660102.
[46] Cano A, Perez-Moreno MA, 
Rodrigo I. et al. The transcription factor 
snail controls epithelialmesenchymal 
transitions by repressing E-cadherin 
expression. Nature Cell Biology. 2000; 2: 
76-83. DOI: 10.1038/35000025.
[47] Carmichel CL, Goossens S, Wang J. 
et al. The EMT Modulator SNAI1 Drives 
AML Development Via Its Interaction 
with the Chromatin Modulator LSD1. 
Blood. 2016; 128 (22): 2688. DOI: 
10.1182/blood.V128.22.2688.2688
[48] Lourenço AN, Roukens MG, 
Seinstra D. et al. C/EBP α is crucial 
determinant of epithelial maintenance 
by preventing epithelial-to- 
mesenchymal transition. Nature 
Communication. 2020; 11: 785. DOI: 
10.1038/s41467-020-14556-x
[49] Yoshida J, Ishikawa T, Endo Y, et 
al. Metformin inhibits TGF β1 induced 
epithelial mesenchymal transition and 
liver metastasis of pancreatic cancer 
cells. Oncology Reports. 2020; 44(1): 
371-381. https://doi.org/10.3892/
or.2020.7595.
[50] Sangodkar J, Farrington CC,  
McClinch K, et al. All roads lead to 
PP2A: Exploiting the therapeutic 
potential of this phosphatase. FEBS 
Journal. 2016; 283: 1004-1024. DOI: 
10.1111/febs.13573.
[51] Neviani P, Santhanam R, Trotta R, 
et al. The tumor suppressor PP2A is 
functionally inactivated in blast crisis 
CML through the inhibitory activity of 
the BCR/ABL-regulated SET protein. 
Сancer Cell. 2005; 8: 355-368. DOI: 
10.1016/j.ccr.2005.10.015.
[52] Voronkov M, Braitwaite SP, 
Stockt JB. Phosphoprotein phosphatase 
2A: a novel druggable target for 
Alzheimer’s disease. Future Medicinal 
Chemistry. 2011; 3: 821-833. DOI: 
10.1007/s11596-020-2140-1
[53] Perrotti D, Cesi V, Trotta R, et al. 
BCR/ABL suppresses C/EBR expression 
through inhibitory action of RNPE2. 
Nature Genetics. 2002; 30: 48-58. DOI: 
10.1038/ng791.
[54] Chang JS, Santhanam R, Trotta R,  
et al. High levels of BCR-ABL 
oncoprotein are required for the MAP-
hnRNP-E2-dependent suppression of C/
EBPα-driven myeloid differentiation. 
Blood. 2007; 10: 994-1002. DOI: 
10.1182/blood-2007-03-078303.
[55] Nieborowska-Skorska M., Hoser G., 
Hochhaus A. et al. Anti-oxidant vitamin 
E prevents accumulation of imatinib-
resistant BCR-ABL1 kinase mutations 
in CML-CP xenografts in NSG mice. 
Leukemia. 2013, 27(11): 2253-2254.  
DOI : 10.1038/leu.2013.123
